PRM32 Development of a Post-Marketing Requirements (PMR) Database  by Mouchet, J. et al.
dependence on the responsiveness of the RWD holder. Further, the findings un-
derscore limited feasibility for assessing outcomes in anti-diabetic drugs without
database linkage, suggesting the need for improved RWDs in Europe.
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OBJECTIVES: To compare the completeness of maternity data from a primary care
database, The Health Improvement Network (THIN), and a secondary care data-
base, Hospital Episodes Statistics (HES). METHODS: From 1998-2009, 2,649 preg-
nancies were identified from one practice in THIN. A group of 15,166 patients in the
same practice was linked to secondary care data from HES and 3,285 pregnancies
were identified from this population. The completeness of recording for maternity
variables within each dataset was compared. RESULTS:Maternal age was recorded
for all pregnancies in both datasets and a measure of social deprivation was re-
corded for over 95% of pregnancies in THIN and HES. Ethnicity recording in THIN
was inconsistent with 56.4% missing or unknown, whilst in HES it was recorded for
75.1% of pregnancies. In THIN, 0.2% of pregnancies had data on the number of
babies compared to 94% of pregnancies in HES. In both datasets, less than 25% of
pregnancies had the number of previous pregnancies recorded. In HES, over 60% of
pregnancies contained data on birth weight, sex of the baby and mode of delivery
compared to fewer than 7% of pregnancies in THIN. Gestational age at birth was
recorded for less than half of pregnancies in both THIN and HES. CONCLUSIONS:
These maternity data are better recorded in HES than in THIN, suggesting possible
benefits from linking the two data sources – primary care provides clinical infor-
mation e.g. medical conditions and prescriptions, whilst secondary care provides
data on pregnancy and birth outcomes. These findings are currently limited to one
practice. Future work includes examining the baby’s records in THIN and HES for
further data, assessing other variables, such as non-live birth outcomes, and ex-
panding the analysis to a larger dataset of THIN-HES linked practices.
PRM29
SUPRAPUBIC PROSTATECTOMY (SP) VERSUS TRANSURETHRAL ENDOSCOPIC
RESECTION OF PROSTATE (TURP): HOSPITALIZATION OUTCOMES AND COSTS
OF BENIGN PROSTATIC HYPERPLASIA USING A PRUBLIC DATABASE (DATASUS)
IN BRAZIL
Barbosa EG, Lowery AP, Santos PA, Machado M
GlaxoSmithKline Ltda, Rio de Janeiro, Rio de Janeiro, Brazil
OBJECTIVES: To evaluate the costs and outcomes of two Benign Prostatic Hyper-
plasia (BPH) surgical procedures available in the public health care system in Brazil.
METHODS: A 3-year longitudinal analysis (2009 to 2011) of an anonymized govern-
ment administrative database (Inpatient Information System - SIH/DATASUS) was
performed. The study cohort comprised all BPH hospitalization registries (ICD10
D299 and N40) from male patients and aged 40 years and over. Patients were
uniquely identified by the following parameters: date of birth, postal code, gender
and ethnicity. Deterministic registry matching was applied. Costs were reported in
2012 Brazilian currency (1BRL0.52USD). Outcomes assessed were reoperation
rates, average in-hospital length-of-stay (in days), and need for intensive care unit
(ICU). Descriptive statistics [i.e., average, standard deviation (SD) and proportions]
summarized studied data. RESULTS: A total of 48,750 patients with average age of
68.38.6 were identified within 3 years of analysis. 21,747 patients were submitted
to SP (total cost BRL27.9 million) and 27,003 to TURP (total cost BRL22.0 million).
There were different proportions of surgical types among Brazilian regions, SP and
TURP, respectively: North (N) 69.5% vs. 30.5%, Northeast (NE) 57.7% vs. 42.3%, Cen-
tral West (CE) 43.3% vs. 58.7%, South (S) 41.3% vs. 58.7% and Southeast (SE) 32.6% vs.
67.4%. SP was linked with longer in-hospital length-of-stay (6.455.29) versus TURP
(3.954.31) and also with an increased proportion of procedures requiring ICU 4.2%
and 2.6%. The rate of reoperation was 0.5% in SP and 1.8% in TURP patients.
CONCLUSIONS: SP compared with TURP procedure was linked with more costs to
public health care system in Brazil, a higher need for ICU utilization and increased
days of hospitalization. Nevertheless, reoperation rates following SP were lower
than TURP. A higher number of SP procedures in different Brazilian regions may be
related to availability/access/discrepancies in the treatment of BPH, lack of tech-
nology and under diagnose.
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OBJECTIVES: To evaluate hospitalization registry and disease costs of benign pros-
tatic hyperplasia (BPH) patients in the public health care system in Brazil.
METHODS: A 3-year longitudinal analysis (2009 to 2011) of an anonymized govern-
ment administrative database (Inpatient Information System - SIH/DATASUS) was
performed. Patients with at least one BPH registry (ICD10 D291/N40) were uniquely
identified by the following parameters: date of birth, postal code, gender, and eth-
nicity and followed over the analysis period to find events associated with BPH.
Patients with prostate/bladder cancer were excluded. Deterministic registry
matching procedures were applied. Costs were reported in 2012 Brazilian currency
(1BRL0.52USD). Outcomes assessed were rehospitalization rates, age and ethnic-
ity distribution. Descriptive statistics [i.e., average, standard deviation (SD) and
proportions] summarized studied data. RESULTS: A total of 55,123 patients (aver-
age 68.48.8 years) were identified throughout the analysis. Age distribution was
15.6% 59 years, 74% 60-79 and 10.4% 80. Ethnicity distribution was: 36.5%
whites, 24.8% Latin, 3.8% Black, 1.1% others and 33.7% without information. Most
patients were admitted to hospital for BPH surgical procedures (88.4%). Percentage
of a second hospitalization due to BPH was 9.9%. Other 2.5% required three or more
hospitalizations. Percentage of total hospitalizations and total costs for BPH asso-
ciated events were: Acute Urinary Retention (AUR): 2.6% and 1.9%, Urinary Tract
Infection (UTI): 2.6% and 1.3%, Urethral Stenosis: 1.9% and 1.0%, Infection and
Inflammation: 0.8% and 0.3%, Renal Failure 0.7% and 1.2% and Others: 2.4% and
2.8%. Total cost was BRL60,7 million (BRL20million yearly) with an average cost of
BRL1,100/patient/year, with age group variations of BRL889 in 40-49 years to
BRL1,147 in 70-79 years. Total cost with BPH associated events was BRL5,1million.
CONCLUSIONS: In Brazil, BPH patients are more frequently hospitalized in age
group 60-79 with a 3-year rehospitalization rate reaching 12.4%. AUR and UTI rep-
resented the most frequent and costly BPH associated events.
PRM31
ASSESSMENT OF ADOPTION OF UNITED STATES PRESCRIBING GUIDELINES FOR
DABIGATRAN IN A REAL WORLD POPULATION
Schrader BJ1, Charland SL1, Malone DC2, Agatep BC1, Herrera V1, Hawk GS1, Stanek EJ1
1Medco Research Institute, LLC/an Express Scripts Company, Bethesda, MD, USA, 2University of
Arizona, Tucson, AZ, USA
OBJECTIVES: Dabigatran is indicated to reduce stroke/ systemic embolism risk in
patients with non-valvular atrial fibrillation (AFIB). Post approval, there has been
much focus on dabigatran safety. Thus, we evaluated dabigatran real world use
and safety in the United States in the context of approved labeling relating to
safety. METHODS: A retrospective evaluation was conducted of de-identified,
pharmacy/medical claims in patients with a new dabigatran prescription claim
during 11/2010-08/2011 and continuous eligibility of 12 months prior and 4-months
after initiation of treatment. Demographic/clinical characteristics of patients, pre-
scriber specialty, and adoption of approved labeling recommendations (renal func-
tion testing, drug interactions, and dosage recommendations) were assessed.
RESULTS: A total of 1,424 patients, mostly males (61.5%), 7311 years old, received
a dabigatran dose of 150mg BID (93.8%), prescribed primarily by a cardiologist
(60.7%). In regards to label guidance, 1090 (77%) patients had a claims history for
AFIB, 19.2% were exposed to medications that increase the serum concentration of
dabigatran, and 20.2% were exposed to medications listed as inhibitors of dabiga-
tran metabolism. Renal function assessment within the prior year was evident in
22.8% of patients (11.3% in pts 75 years old), and over 4 months of f/u in 12.3%
(6.1% in pts 75 years old). Additionally, only 48.8% of patients with a creatinine
clearance 30 mL/min received 75 mg BID. CONCLUSIONS: Despite specific dab-
igatran labeling recommendations, a high percentage of prescribers are not follow-
ing the guidance for: indications; dosage adjustment for interacting drugs, renal
function, or age; or, renal function monitoring, which may adversely affect stroke
or bleeding outcomes. Ongoing review and action on dabigatran prescribing and
monitoring to optimize safe clinical outcomes in a real world population are
needed.
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OBJECTIVES: Post-marketing surveillance for adverse effects has become an essen-
tial element of new drug and medical devices development in the European Union
and the USA. The objective of this study is to present an overview of the content of
a database that gathers details of Post-Marketing Requirements (PMRs), i.e., studies
requested by the following regulatory agencies: European Medicines Agency (EMA,
EU); the Food and Drug Administration (FDA, USA); and the Haute Autorité de Santé
(HAS, France). METHODS: All drug approvals published by the EMA, the FDA, and
the HAS between January 1, 2005 and December 31, 2011 were reviewed to retrieve
PMRs. The information was categorized as follows: product description (brand
name, INN, indication, etc.); application details; PMR details; and information
source. RESULTS: For the FDA, we reviewed 763 original approvals and 944 supple-
ments and included, respectively, 201 and 110 drugs approved with PMRs. For the
EMA, we reviewed 349 marketing authorizations and included 38 files with PMRs.
For the HAS, 3674 opinions were published with only 174 opinions with PMRs. Many
HAS requests were long-term follow-up studies. About 43% of the PMRs requested
by the FDA were pediatric studies. At present, the EMA also requires pediatric
studies but under a Pediatric Investigation Plan (PIP). Since 2005, 21 PIPs have been
requested. No matter which agency is reviewed, all kinds of indications are covered
by the PMRs, e.g., treatment of sepsis, asthma, depressive disorder, etc.
CONCLUSIONS: This project will be a unique source of centralized information
about PMRs requested in Europe and in the USA. It will be useful to observe the
trends in studies requested, to anticipate the demands, and to integrate the studies
as early as possible in the product development process. The Post-Marketing Re-
quirements database will be available online in an independent website, with ac-
cess by subscription.
PRM33
REAL WORLD EVIDENCE: PROMISE AND PITFALLS OF REAL WORLD DATA
Weir S1, Langham S1, Ratcliffe M2
1PHMR Associates Ltd, London, UK, 2PHMR Associates, London, UK
OBJECTIVES: Clinical trials remain the gold standard for proving efficacy but re-
strictive enrolment criteria and overly controlled study environments limit gener-
alizability. Increasingly, payers and health care providers are interested in real
world evidence to support the case for pharmaceutical innovations. We review
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